Advances in immunotherapy have revolutionized cancer treatment, yet many patients do not
show clinical responses. While most immunotherapies target T cells, myeloid cells are the …

Sialic-acid-binding immunoglobulin-type lectins (Siglecs) are a family of cell-surface
immunomodulatory receptors that recognize sialic-acid-containing glycans. The majority of …

Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate
cancer. Sialyltransferases have been shown across several solid tumours, including breast …

Targeting “undruggable” targets with intrinsically disordered structures is of great
significance for the treatment of disease. The transcription factor c‐Myc controls global gene …

Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms
which promote tumor growth and progression. Specifically, the interactions of sialic acids …

Siglec-7 (sialic acid–binding immunoglobulin-like lectin 7) is a glycan-binding immune
receptor that is emerging as a significant target of interest for cancer immunotherapy. The …

Prostate cancer is the second leading cause of male cancer death in the US Current
immune checkpoint inhibitor–based immunotherapies have improved survival for many …

MYC activation is a known hallmark of cancer as it governs the gene targets involved in
various facets of cancer progression. Of interest, MYC governs oncometabolism through the …

Simple Summary Tumor cells accumulate sialylation in tissues via the coordination of
sialyltransferases and sialidases. Tumor sialylation can block receptor and ligand binding at …

Cells in the tumor microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) show
enormous diversity and plasticity, with functions that can range from tumor inhibitory to tumor …